

Sebastian Ochsenreither

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/490166/publications.pdf>

Version: 2024-02-01

25
papers

478
citations

932766

10
h-index

713013

21
g-index

26
all docs

26
docs citations

26
times ranked

743
citing authors

#	ARTICLE	IF	CITATIONS
1	First interim analysis of the SirTac trial: A randomized phase II study of SIRT and DSM-TACE in patients with liver metastases from uveal melanoma.. Journal of Clinical Oncology, 2022, 40, 9511-9511.	0.8	4
2	FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A).. Journal of Clinical Oncology, 2022, 40, 9510-9510.	0.8	22
3	KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 737-752.	1.3	28
4	Disulfiram Acts as a Potent Radio-Chemo Sensitizer in Head and Neck Squamous Cell Carcinoma Cell Lines and Transplanted Xenografts. Cells, 2021, 10, 517.	1.8	20
5	Carcinoma of Unknown Primary and the 8th Edition <sc>TNM</sc> Classification for Head and Neck Cancer. Laryngoscope, 2021, 131, E2534-E2542.	1.1	8
6	FDG-PET/CT for pretherapeutic lymph node staging in non-small cell lung cancer: A tailored approach to the ESTS/ESMO guideline workflow. Lung Cancer, 2021, 157, 66-74.	0.9	6
7	Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥50%) NSCLC: Real-world Results with Special Focus on PS ≥2, Brain Metastases, and Steroids. Clinical Lung Cancer, 2021, 22, 411-422.	1.1	11
8	First-In-Human Phase I Study of a Next-Generation, Oral, TGF β 2 Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. Clinical Cancer Research, 2021, 27, 6666-6676.	3.2	27
9	Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis. Clinical Lung Cancer, 2020, 21, e607-e621.	1.1	32
10	Distinct immune evasion in <sc>APOBEC</sc>-enriched, <sc>HPV</sc>-negative <sc>HNSCC</sc>. International Journal of Cancer, 2020, 147, 2293-2302.	2.3	10
11	Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivo. Cancer Immunology, Immunotherapy, 2020, 69, 1217-1227.	2.0	8
12	Support of a molecular tumour board by an evidence-based decision management system for precision oncology. European Journal of Cancer, 2020, 127, 41-51.	1.3	25
13	Local ablative treatment for synchronous single organ oligometastatic lung cancer—A propensity score analysis of 180 patients. Lung Cancer, 2018, 125, 164-173.	0.9	27
14	pN status predicts outcomes in surgically treated pT1–pT2 patients of various disease stages with squamous cell carcinoma of the head and neck: a 17-year retrospective single center cohort study. European Archives of Oto-Rhino-Laryngology, 2018, 275, 2787-2795.	0.8	6
15	Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology, The, 2017, 18, 323-335.	5.1	173
16	STREAM: A randomized discontinuation, blinded, placebo-controlled phase II study of sorafenib (S) treatment of chemonaïve patients (pts) with metastatic uveal melanoma (MUM).. Journal of Clinical Oncology, 2017, 35, 9511-9511.	0.8	12
17	Association of an APOBEC mutational signature, mutational load, and BRCAness with inflammation and PD-L1 expression in HNSCC.. Journal of Clinical Oncology, 2017, 35, e14613-e14613.	0.8	2
18	A phase I study of the bispecific antibody T-cell engager GBR 1302 in subjects with HER2-positive cancers.. Journal of Clinical Oncology, 2017, 35, TPS3091-TPS3091.	0.8	6

#	ARTICLE	IF	CITATIONS
19	Association of methylation of homologous repair genes with expression of immune checkpoints in squamous cell carcinoma of head and neck, lung and cervix.. Journal of Clinical Oncology, 2016, 34, 11543-11543.	0.8	0
20	Collecting wisdom: Creating an evidence framework for personalized cancer therapy.. Journal of Clinical Oncology, 2016, 34, e23141-e23141.	0.8	0
21	Immunomodulatory effects of 5-azacytidine in acute myeloid leukemia.. Journal of Clinical Oncology, 2014, 32, 3083-3083.	0.8	1
22	Cyclin-A1 expression in acute myeloid leukemia stem cells and its representation as an immunogenic antigen that can be targeted by cytotoxic T cells.. Journal of Clinical Oncology, 2012, 30, 2523-2523.	0.8	0
23	Comparison of T-cell receptor repertoire restriction in blood and tumor tissue of colorectal cancer patients. Journal of Translational Medicine, 2010, 8, 35.	1.8	9
24	Melting Point Assay for the JAK2 V617F Mutation, Comparison with Amplification Refractory Mutation System (ARMS) in Diagnostic Samples, and Implications for Daily Routine. Molecular Diagnosis and Therapy, 2010, 14, 185-190.	1.6	5
25	Extrapulmonary small cell carcinoma (EPSCC): 10 years' multi-disciplinary experience at CharitÄ©. Anticancer Research, 2009, 29, 3411-5.	0.5	36